Correction

SECTM1 is upregulated in immuno-hot tumors and predicts immunotherapeutic efficacy in multiple cancers

Jie Mei, Ziyi Fu, Yun Cai, Chenghu Song, Jiaofeng Zhou, Yichao Zhu, Wenjun Mao,* Junying Xu,* and Yongmei Yin*

(iScience 26, 106027; February 17, 2023)

In the originally published version of this article, in Figure 3F, the FC and P values were mistakenly imported into the NDB group. The figure has been updated to reflect the correct values.

Additionally, in the Figure 5C legend, significance was calculated with Kruskal-Wallis test with Dunn's multiple-comparison test, but this was mistakenly written as "Significance was calculated with Kruskal-Wallis test with Tukey's multiple-comparison test."

These errors have now been corrected in the article online. The authors apologize for any confusion these errors may have caused.

*Correspondence: maowenjun1@njmu.edu.cn (W.M.), doctorxjy123@163.com (J.X.), ymyin@njmu.edu.cn (Y.Y.)
https://doi.org/10.1016/j.isci.2023.108302

Figure 3. Predictive value and immunological correlations of SECTM1 in six cohorts (original)

Figure 3. Predictive value and immunological correlations of SECTM1 in six cohorts (corrected)